T2D Blood Transcriptomics Biomarker Evidence

Tkachenko et al. 2025 reports meta-analytic blood transcriptomic signals and provides a strong warning that T2D blood transcriptomic biomarker claims are unstable when inferred from individual cohorts.

Evidence Synthesis

Evidence PointSourceInterpretation for This Paper
Individual-study DEG lists were poorly concordant across eight blood RNA-seq datasets.[[references/tkachenko-2025-cross-study-blood-transcriptomes-t2dTkachenko et al. 2025]]
Meta-analysis recovered 2065 DEGs and 713 integration-driven discoveries.[[references/tkachenko-2025-cross-study-blood-transcriptomes-t2dTkachenko et al. 2025]]
Enriched pathways included neutrophil degranulation, TNF-alpha signaling, oxidative phosphorylation, mTOR signaling, ERAD, oxidative stress, and RNA splicing.[[references/tkachenko-2025-cross-study-blood-transcriptomes-t2dTkachenko et al. 2025]]
The paper includes PBMC and whole-blood datasets together.[[references/tkachenko-2025-cross-study-blood-transcriptomes-t2dTkachenko et al. 2025]]
The paper does not test ancestry-stratified effects.[[references/tkachenko-2025-cross-study-blood-transcriptomes-t2dTkachenko et al. 2025]]

Candidate Claims For Manuscript Support

  • Blood transcriptomic studies of T2D show substantial cross-study heterogeneity.
  • Cross-study integration can identify pathways and genes missed in individual cohorts.
  • Immune and stress-response pathways, including neutrophil effector biology, ER-stress/ERAD, mTOR, oxidative stress, and RNA splicing, appear relevant to T2D blood transcriptomic signatures; this is pathway-enrichment evidence, not diagnostic validation or PBMC-specific proof.
  • PBMC ancestry claims should explicitly separate sample-type biology, cohort composition, and technical batch effects from ancestry-associated biology.

Claim Discipline

  • Use this source for limitations and replication framing.
  • Do not use this source as direct evidence of ancestry-associated immune differences.
  • Treat neutrophil terms cautiously in PBMC-focused prose unless the project has direct evidence for granulocyte-related signal.